Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 81 articles:
HTML format



Single Articles


    June 2021
  1. OP DEN WINKEL M, Nagel D, de la Torre Alaez MA, Hempe S, et al
    A simple prognostic scoring system for hepatocellular carcinoma treated with selective internal radiation therapy.
    Dig Dis. 2021 Jun 10. pii: 000517458. doi: 10.1159/000517458.
    PubMed    


    May 2021
  2. KRSTIC MN, Mijac D, Tomasevic RS, Lukic S, et al
    Abnormal liver blood tests: Hepatologist approach.
    Dig Dis. 2021 May 10. pii: 000517110. doi: 10.1159/000517110.
    PubMed    


    April 2021
  3. MEYER JJ, Dreyhaupt J, Schwerdel D, Ettrich TJ, et al
    Blood-based targeted metabolomics discriminate patients with alcoholic liver cirrhosis from those with non-cirrhotic liver damage: an explorative study.
    Dig Dis. 2021 Apr 16. pii: 000516488. doi: 10.1159/000516488.
    PubMed    


  4. MANZHALII E, Falalyeyeva TM, Moyseyenko VO, Weiskirchen R, et al
    Elevation of autoantibodies to cerebral proteins in hepatic encephalopathy: Another pathogenic factor?
    Dig Dis. 2021 Apr 9. pii: 000516412. doi: 10.1159/000516412.
    PubMed     Abstract available


    January 2021
  5. KUSNIK A, Hunter N, Rasbach E, Miethke T, et al
    Co-Medication and nutrition in HCC: Potentially preventative strategies in Hepatocellular carcinoma (HCC).
    Dig Dis. 2021 Jan 11. pii: 000514277. doi: 10.1159/000514277.
    PubMed     Abstract available


  6. ANASTASIOU OE, Korth J, Herbstreit F, Witzke O, et al
    Mild versus Severe Liver Injury in SARS-CoV-2 Infection.
    Dig Dis. 2021;39:52-57.
    PubMed     Abstract available


  7. WEBER S, Benesic A, Buchholtz ML, Rotter I, et al
    Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver Injury.
    Dig Dis. 2021;39:275-282.
    PubMed     Abstract available


  8. XU Y, Hu X, Li J, Dong R, et al
    An Improved Scoring System Based on Platelet-Albumin-Bilirubin in Predicting Posthepatectomy Liver Failure Outcomes.
    Dig Dis. 2021;39:258-265.
    PubMed     Abstract available


  9. WADA N, Uojima H, Satoh T, Okina S, et al
    Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
    Dig Dis. 2021;39:234-242.
    PubMed     Abstract available


    November 2020
  10. IDILMAN R, Aydogan M, Oruncu MB, Kartal A, et al
    NATURAL HISTORY OF CIRRHOSIS: CHANGING TRENDS IN ETIOLOGY OVER THE YEARS.
    Dig Dis. 2020 Nov 3. pii: 000512746. doi: 10.1159/000512746.
    PubMed     Abstract available


  11. SCHINDLER P, Masthoff M, Harders F, Schmidt H, et al
    EFFICACY OF 90Y-RADIOEMBOLIZATION IN METASTATIC COLORECTAL CANCER DEPENDING ON THE PRIMARY TUMOR SIDE.
    Dig Dis. 2020 Nov 3. pii: 000512744. doi: 10.1159/000512744.
    PubMed     Abstract available


    September 2020
  12. BARABAS L, Hritz I, Istvan G, Tulassay Z, et al
    The behavior of MMP-2, MMP-7, MMP-9 and their inhibitors TIMP-1, TIMP-2 in adenoma-colorectal cancer sequence.
    Dig Dis. 2020 Sep 22. pii: 000511765. doi: 10.1159/000511765.
    PubMed     Abstract available


    August 2020
  13. MOON AM, Watkins SE, Lok AS, Firpi-Morell RJ, et al
    Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease.
    Dig Dis. 2020 Aug 24. pii: 000511074. doi: 10.1159/000511074.
    PubMed     Abstract available


  14. RAMRAKHIANI NS, Le M, Yeo YH, Le A, et al
    Validity of International Classification of Diseases, 10th Revision, Codes for Cirrhosis.
    Dig Dis. 2020 Aug 19. pii: 000510981. doi: 10.1159/000510981.
    PubMed     Abstract available


    May 2020
  15. KIMURA N, Tsuchiya A, Oda C, Kimura A, et al
    Visceral adipose tissue index and hepatocellular carcinoma are independent predictors of outcome in patients with cirrhosis having endoscopic treatment for esophageal varices.
    Dig Dis. 2020 May 25. pii: 000508867. doi: 10.1159/000508867.
    PubMed     Abstract available


    March 2020
  16. MILOVANOVIC T, Popovic D, Stojkovic Lalosevic M, Dumic I, et al
    Quality Of Life in Patients With Primary Biliary Cholangitis: A Single Center Experience in Serbia.
    Dig Dis. 2020 Mar 6. pii: 000506980. doi: 10.1159/000506980.
    PubMed     Abstract available


  17. KANG MK, Kim KO, Kim MC, Park JG, et al
    Sarcopenia is a new risk factor of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Dig Dis. 2020 Mar 5. pii: 000506938. doi: 10.1159/000506938.
    PubMed     Abstract available


    February 2020
  18. AINORA ME, Iezzi R, Ponziani FR, Garcovich M, et al
    Contrast-enhanced ultrasound in the short-term evaluation of hepatocellular carcinoma after locoregional treatment.
    Dig Dis. 2020 Feb 13. pii: 000506455. doi: 10.1159/000506455.
    PubMed     Abstract available


    January 2020
  19. SINGH SK, Sen Sarma M, Yachha SK, Srivastava A, et al
    Late-Onset Hepatic Failure in Children: Risk Factors that Determine the Outcome.
    Dig Dis. 2020 Jan 15:1-6. doi: 10.1159/000505124.
    PubMed     Abstract available


  20. DITE P, Blaho M, Bojkova M, Jabandziev P, et al
    Nonalcoholic Fatty Pancreas Disease: Clinical Consequences.
    Dig Dis. 2020;38:143-149.
    PubMed     Abstract available


  21. BLACKETT JW, Verna EC, Lebwohl B
    Increased Prevalence of Colorectal Adenomas in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.
    Dig Dis. 2020;38:222-230.
    PubMed     Abstract available


    December 2019
  22. ARORA MS, Kaushik R, Ahmad S, Kaushik RM, et al
    Profile of Acute Kidney Injury in Patients with Decompensated Cirrhosis at a Tertiary-Care Center in Uttarakhand, India.
    Dig Dis. 2019 Dec 12:1-9. doi: 10.1159/000504836.
    PubMed     Abstract available


  23. OGURA T, Yamada T, Yamada M, Ueno S, et al
    Triple Covered Metal Stent Deployment Using Side-by-Side Technique for Hemobilia due to Hepatocellular Carcinoma (with Video).
    Dig Dis. 2019 Dec 12:1-4. doi: 10.1159/000504384.
    PubMed     Abstract available


    October 2019
  24. REICHERT MC, Schulz A, Massmann A, Buecker A, et al
    Predictive Power of Liver Maximum Function Capacity Test in Transjugular Intrahepatic Portosystemic Shunt Patients: A Pilot Study.
    Dig Dis. 2019 Oct 16:1-8. doi: 10.1159/000503098.
    PubMed     Abstract available


  25. MONTES-CORTES DH, Olivares-Corichi IM, Rosas-Barrientos JV, Manuel-Apolinar L, et al
    Characterization of Oxidative Stress and Ammonia According to the Different Grades of Hepatic Encephalopathy.
    Dig Dis. 2019 Oct 2:1-11. doi: 10.1159/000503097.
    PubMed     Abstract available


    June 2019
  26. UOJIMA H, Hidaka H, Tanaka Y, Wada N, et al
    Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis.
    Dig Dis. 2019 Jun 19:1-8. doi: 10.1159/000501267.
    PubMed     Abstract available


  27. LASHEN SA, Shamseya MM, Madkour MA
    Hepatocellular Carcinoma Occurrence/Recurrence after Direct-Acting Antivirals for Hepatitis C in Egyptian Cohort: Single-Center Experience.
    Dig Dis. 2019 Jun 19:1-10. doi: 10.1159/000501072.
    PubMed     Abstract available


  28. FACCIORUSSO A, Buccino VR, Del Prete V, Antonino M, et al
    Cirrhosis Is a Predictor of Adverse Events in Endoscopic Ultrasound Fine-Needle Aspiration: A Propensity-Score Analysis.
    Dig Dis. 2019 Jun 18:1-8. doi: 10.1159/000501268.
    PubMed     Abstract available


  29. MANZHALII E, Virchenko O, Falalyeyeva T, Moiseienko V, et al
    Hepatic Encephalopathy Aggravated by Systemic Inflammation.
    Dig Dis. 2019 Jun 6:1-9. doi: 10.1159/000500717.
    PubMed     Abstract available


    January 2019
  30. AZUMA S, Asahina Y, Kakinuma S, Azuma K, et al
    Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2019 Jan 9:1-8. doi: 10.1159/000493580.
    PubMed     Abstract available


  31. KIDA Y
    Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Dig Dis. 2019 Jan 9:1-8. doi: 10.1159/000494438.
    PubMed     Abstract available


  32. SHIRIN D, Peleg N, Sneh-Arbib O, Cohen-Naftaly M, et al
    The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities.
    Dig Dis. 2019;37:69-76.
    PubMed     Abstract available


  33. CAMPOS AMICO E, de Souza IK, Grigorio Trigueiro JR, Cunha Miranda F, et al
    Should Focal Nodular Hyperplasia Still be Operated Upon? Analysis of a Case Series.
    Dig Dis. 2019;37:309-314.
    PubMed     Abstract available


  34. SERRANO CA, Ling SC, Verdaguer S, Leon M, et al
    Portal Angiogenesis in Chronic Liver Disease Patients Correlates with Portal Pressure and Collateral Formation.
    Dig Dis. 2019;37:498-508.
    PubMed     Abstract available


    November 2018
  35. SCHULZ C, Schutte K, Vilchez-Vargas R, Vasapolli R, et al
    Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Dig Dis. 2018 Nov 14:1-9. doi: 10.1159/000494216.
    PubMed     Abstract available


    September 2018
  36. GOTTLIEB A, Kottmann M, Manka P, Bedreli S, et al
    How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis.
    Dig Dis. 2018 Sep 18:1-8. doi: 10.1159/000492869.
    PubMed     Abstract available


    July 2018
  37. BUTTERWORTH RF, Canbay A
    Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2018 Jul 17:1-6. doi: 10.1159/000491429.
    PubMed     Abstract available


  38. LONGO L, de Freitas LBR, Santos D, Grivicich I, et al
    Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.
    Dig Dis. 2018 Jul 13:1-8. doi: 10.1159/000490378.
    PubMed     Abstract available


  39. FURUTA M, Moriguchi M, Okuda K, Kataoka S, et al
    Impact of Insufficient Response with an Increase in Tumor Number in Predicting Transcatheter Arterial Chemoembolization Refractoriness for Hepatocellular Carcinoma.
    Dig Dis. 2018 Jul 3:1-10. doi: 10.1159/000489488.
    PubMed     Abstract available


    May 2018
  40. TAJIRI K, Tokimitsu Y, Ito H, Atarashi Y, et al
    Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Dig Dis. 2018 May 31:1-8. doi: 10.1159/000489258.
    PubMed     Abstract available


    March 2018
  41. ZOU H, Yang X, Li QL, Zhou QX, et al
    A Comparative Study of Albumin-Bilirubin Score with Child-Pugh Score, Model for End-Stage Liver Disease Score and Indocyanine Green R15 in Predicting Posthepatectomy Liver Failure for Hepatocellular Carcinoma Patients.
    Dig Dis. 2018 Mar 1. pii: 000486590. doi: 10.1159/000486590.
    PubMed     Abstract available


    January 2018
  42. HUANG XW, Liao B, Huang Y, Liang JY, et al
    Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?
    Dig Dis. 2018 Jan 19. pii: 000486196. doi: 10.1159/000486196.
    PubMed     Abstract available


  43. BUECHTER M, Manka P, Gerken G, Canbay A, et al
    Transjugular Intrahepatic Portosystemic Shunt in Patients with Portal Hypertension: Patency Depends on Coverage and Interventionalist's Experience.
    Dig Dis. 2018 Jan 9. pii: 000486030. doi: 10.1159/000486030.
    PubMed     Abstract available


  44. BAI L, Jin W, Kong M, Zhang X, et al
    Injury Resistance in the Setting of Liver Fibrosis Is Accompanied by the Inhibition of High-Mobility Group Box-1 Translocation and Release.
    Dig Dis. 2018;36:167-176.
    PubMed     Abstract available


  45. TAKATORI Y, Kato M, Sunata Y, Hirai Y, et al
    The Role of History of Gastro-Duodenal Ulcer in Patients with Upper Gastrointestinal Bleeding.
    Dig Dis. 2018;36:177-181.
    PubMed     Abstract available


  46. PAN X, Han Y, Zou T, Zhu G, et al
    Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis.
    Dig Dis. 2018;36:427-436.
    PubMed     Abstract available


  47. NISHIOKA Y, Shindoh J, Inagaki Y, Gonoi W, et al
    Host MICA Polymorphism as a Potential Predictive Marker in Response to Chemotherapy for Colorectal Liver Metastases.
    Dig Dis. 2018;36:437-445.
    PubMed     Abstract available


    November 2017
  48. SHI L, Zhang X, Li J, Bai X, et al
    Favorable Effects of Endoscopic Ligation Combined with Drugs on Rebleeding and Mortality in Cirrhotic Patients: A Network Meta-Analysis.
    Dig Dis. 2017 Nov 21. doi: 10.1159/000484082.
    PubMed     Abstract available


    October 2017
  49. DYWICKI J, Noyan F, Misslitz AC, Hapke M, et al
    Hepatic T Cell Tolerance Induction in An Inflammatory Environment.
    Dig Dis. 2017 Oct 12. doi: 10.1159/000481341.
    PubMed     Abstract available


    July 2017
  50. XIAO W, Zheng J, Zhou B, Pan L, et al
    Replication Protein A 3 Is Associated with Hepatocellular Carcinoma Tumorigenesis and Poor Patient Survival.
    Dig Dis. 2017 Jul 7. doi: 10.1159/000478977.
    PubMed     Abstract available


  51. LABENZ C, Prenosil V, Koch S, Huber Y, et al
    Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Dig Dis. 2017 Jul 4. doi: 10.1159/000477578.
    PubMed     Abstract available


    January 2017
  52. PERUGORRIA MJ, Labiano I, Esparza-Baquer A, Marzioni M, et al
    Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
    Dig Dis. 2017;35:275-281.
    PubMed     Abstract available


  53. LARUSSO NF, Tabibian JH, O'Hara SP
    Role of the Intestinal Microbiome in Cholestatic Liver Disease.
    Dig Dis. 2017;35:166-168.
    PubMed     Abstract available


  54. REICH M, Klindt C, Deutschmann K, Spomer L, et al
    Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage.
    Dig Dis. 2017;35:235-240.
    PubMed     Abstract available


  55. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    PubMed     Abstract available


  56. STEINACHER D, Claudel T, Trauner M
    Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2017;35:282-287.
    PubMed     Abstract available


  57. HALILBASIC E, Steinacher D, Trauner M
    Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
    Dig Dis. 2017;35:288-292.
    PubMed     Abstract available


  58. PALLEN MJ, Quraishi MN
    The Gut Microbiota and the Hepatologist: Will Our Bugs Prove to be the Missing Link?
    Dig Dis. 2017;35:377-383.
    PubMed     Abstract available


  59. GALLE PR
    Treating Hepatobiliary Cancers: The Oncology Way.
    Dig Dis. 2017;35:384-386.
    PubMed     Abstract available


  60. POSE E, Cardenas A
    Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Dig Dis. 2017;35:402-410.
    PubMed     Abstract available


  61. DUFFY AG, Greten TF
    Treating Hepatobiliary Cancer: The Immunologic Approach.
    Dig Dis. 2017;35:390-396.
    PubMed     Abstract available


  62. NEVENS F
    Novel Approaches to Reducing the Risk of Variceal Hemorrhage.
    Dig Dis. 2017;35:397-401.
    PubMed     Abstract available


  63. ROWE IA
    Lessons from Epidemiology: The Burden of Liver Disease.
    Dig Dis. 2017;35:304-309.
    PubMed     Abstract available


  64. TOWNSEND SA, Newsome PN
    The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016.
    Dig Dis. 2017;35:371-376.
    PubMed     Abstract available


  65. CHUNG BK, Karlsen TH
    Genetic Discoveries Highlight Environmental Factors as Key Drivers of Liver Disease.
    Dig Dis. 2017;35:323-333.
    PubMed     Abstract available


  66. WONG LL, Hegade VS, Jones DEJ
    What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Dig Dis. 2017;35:359-366.
    PubMed     Abstract available


  67. THORGEIRSSON SS
    Stemness in Liver Cancer.
    Dig Dis. 2017;35:387-389.
    PubMed     Abstract available


  68. BAWDEN SJ, Scott RA, Aithal GP
    Current and Future Magnetic Resonance Technologies for Assessing Liver Disease in Clinical and Experimental Medicine.
    Dig Dis. 2017;35:314-322.
    PubMed     Abstract available


  69. IREDALE JP, Pellicoro A, Fallowfield JA
    Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.
    Dig Dis. 2017;35:310-313.
    PubMed     Abstract available


  70. HIRAOKA A, Kumada T, Kudo M, Hirooka M, et al
    Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
    Dig Dis. 2017;35:602-610.
    PubMed     Abstract available


  71. NISHIDA N, Kudo M
    Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma.
    Dig Dis. 2017;35:618-622.
    PubMed     Abstract available


  72. UESHIMA K, Nishida N, Kudo M
    Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
    Dig Dis. 2017;35:611-617.
    PubMed     Abstract available


  73. ISHIKAWA T, Imai M, Owaki T, Sato H, et al
    Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study.
    Dig Dis. 2017;35:598-601.
    PubMed     Abstract available


  74. ARIZUMI T, Minami T, Chishina H, Kono M, et al
    Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Dig Dis. 2017;35:589-597.
    PubMed     Abstract available


  75. ARIZUMI T, Minami T, Chishina H, Kono M, et al
    Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
    Dig Dis. 2017;35:583-588.
    PubMed     Abstract available


  76. IWAMOTO T, Imai Y, Igura T, Kogita S, et al
    Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellula
    Dig Dis. 2017;35:574-582.
    PubMed     Abstract available


  77. IDA H, Hagiwara S, Kono M, Minami T, et al
    Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Dig Dis. 2017;35:565-573.
    PubMed     Abstract available


  78. UMEHARA Y, Hagiwara S, Nishida N, Sakurai T, et al
    Hepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis C.
    Dig Dis. 2017;35:548-555.
    PubMed     Abstract available


  79. KOBAYASHI N, Kumada T, Toyoda H, Tada T, et al
    Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Dig Dis. 2017;35:521-530.
    PubMed     Abstract available


  80. KITAHATA S, Hiraoka A, Kudo M, Murakami T, et al
    Abdominal Ultrasound Findings of Tumor-Forming Hepatic Malignant Lymphoma.
    Dig Dis. 2017;35:498-505.
    PubMed     Abstract available


  81. YADA N, Tamaki N, Koizumi Y, Hirooka M, et al
    Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease.
    Dig Dis. 2017;35:515-520.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: